Randomized, Open-Label, Active Comparator, Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Hepatitis B Virus (HBV) Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic HBV Infection
Latest Information Update: 05 Jan 2023
At a glance
- Drugs NCO-48 Fumarate (Primary) ; Tenofovir alafenamide
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Nucorion Pharmaceuticals
- 03 Jan 2023 Status changed from active, no longer recruiting to completed.
- 08 Nov 2022 Interim Results (n=12) assessing : Safety, tolerability, pharmacokinetics (PK), and anti-HBV activity of multiple daily oral doses of NCO 48F compared with in adult subjects with treatment naive HBV infection TAF presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases
- 23 Jun 2022 Planned End Date changed from 1 Aug 2022 to 1 Dec 2022.